Francesca Ghilotti
Milan, 20126, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Comparative Efficacy of Talquetamab vs. Real-World Physician's Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMent.
Journal: Advances in therapy
Published: September 02, 2025
Survival Outcomes with Cilta-cel Versus Conventional Treatment Regimens for Patients with Lenalidomide-Refractory Multiple Myeloma Using Inverse Probability of Treatment Weighting.
Journal: Advances in therapy
Published: April 30, 2025
Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting.
Journal: Journal of comparative effectiveness research
Published: August 20, 2024
A brief report on stable disease among amivantamab-treated patients with post-platinum epidermal growth factor receptor exon 20 insertion-mutated non-small cell lung cancer: A response-based analysis from the CHRYSALIS study.
Journal: Cancer treatment and research communications
Published: March 04, 2024
Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma.
Journal: Advances in therapy
Published: October 06, 2023
Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma.
Journal: Advances in therapy
Published: December 06, 2022
Prospective study of weight loss and all-cause-, cardiovascular-, and cancer mortality.
Journal: Scientific reports
Published: December 01, 2022
Ciltacabtagene Autoleucel for Patients With Triple-class Exposed Multiple Myeloma: Adjusted Comparison of CARTITUDE-1 Patient Outcomes Versus Real-world Clinical Practice.
Journal: HemaSphere
Published: July 06, 2022
Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice.
Journal: Haematologica
Published: December 14, 2021
Adjusted Comparison of Outcomes between Patients from CARTITUDE-1 versus Multiple Myeloma Patients with Prior Exposure to PI, Imid and Anti-CD-38 from a German Registry.
Journal: Cancers
Published: September 20, 2021
Corrigendum to: Obesity and risk of infections: results from men and women in the Swedish National March Cohort.
Journal: International journal of epidemiology
Published: February 18, 2020
Prospective study of job stress and risk of infections in Swedish adults.
Journal: Occupational and environmental medicine
Published: February 18, 2020
Last Updated: 09/26/2026